Insmed Raises Peak Revenue Estimates as BRINSUPRI and TPIP Show Strong Growth — Insmed Incorporated

Event summary

Insmed reported $425.5 million in total revenues for Q2 2026, up 296% year-over-year.
BRINSUPRI revenue grew 49% quarter-over-quarter to $309.2 million.
ARIKAYCE revenue increased 8% year-over-year to $116.3 million.
Insmed raised its peak revenue estimate for BRINSUPRI to over $7 billion and for TPIP to over $6 billion.

The big picture

Insmed's strong Q2 2026 results reflect the growing market acceptance of BRINSUPRI in non-cystic fibrosis bronchiectasis (NCFB) and ARIKAYCE in Mycobacterium avium complex (MAC) lung disease. The company's raised peak revenue estimates for its lead programs highlight its strategic focus on expanding into high-value respiratory indications. Insmed's pipeline, particularly TPIP, positions it to capitalize on unmet needs in pulmonary hypertension and interstitial lung diseases.

What we're watching

Regulatory Milestones: The pace at which Insmed secures regulatory approvals for BRINSUPRI in Japan and potential label expansions for ARIKAYCE in the U.S. and Japan will impact its commercial strategy.
Clinical Development: Progress in Phase 3 trials for TPIP across multiple indications, including PH-ILD, PAH, PPF, and IPF, will determine the pipeline's long-term revenue potential.
Commercial Execution: Insmed's ability to sustain BRINSUPRI's strong U.S. launch momentum and expand its international reach will be critical for meeting revised revenue guidance.